Back to Search
Start Over
Generation of a recombinant Newcastle disease virus expressing two foreign genes for use as a multivalent vaccine and gene therapy vector.
- Source :
-
Vaccine [Vaccine] 2018 Aug 06; Vol. 36 (32 Pt B), pp. 4846-4850. Date of Electronic Publication: 2018 Jun 30. - Publication Year :
- 2018
-
Abstract
- Newcastle disease virus (NDV) has been used as a vector in the development of vaccines and gene therapy. A majority of these NDV vectors express only a single foreign gene through either an independent transcription unit (ITU) or an internal ribosomal entry site (IRES). In the present study, we combined the ITU and IRES methods to generate a novel NDV LaSota strain-based recombinant virus vectoring the red fluorescence protein (RFP) and the green fluorescence protein (GFP) genes. Biological assessments of the recombinant virus, rLS/IRES-RFP/GFP, showed that it was slightly attenuated in vivo, yet maintained similar growth dynamics and viral yields in vitro when compared to the parental LaSota virus. Expression of both the RFP and GFP was detected from the rLS/IRES-RFP/GFP virus-infected DF-1 cells by fluorescence microscopy. These data suggest that the rLS/IRES-RFP/GFP virus may be used as a multivalent vector for the development of vaccines and gene therapy agents.<br /> (Published by Elsevier Ltd.)
- Subjects :
- Animals
Genetic Vectors
Green Fluorescent Proteins genetics
Green Fluorescent Proteins metabolism
Internal Ribosome Entry Sites genetics
Internal Ribosome Entry Sites physiology
Luminescent Proteins genetics
Luminescent Proteins metabolism
Newcastle Disease immunology
Newcastle Disease prevention & control
Newcastle disease virus immunology
Viral Vaccines therapeutic use
Red Fluorescent Protein
Newcastle Disease genetics
Newcastle disease virus genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1873-2518
- Volume :
- 36
- Issue :
- 32 Pt B
- Database :
- MEDLINE
- Journal :
- Vaccine
- Publication Type :
- Academic Journal
- Accession number :
- 30037477
- Full Text :
- https://doi.org/10.1016/j.vaccine.2018.06.055